BUZZ-NovaBridge rises as cancer drug shows promise in early trial** Shares of drug developer NovaBridge NBP.O rise 6.41% to $4.65 premarket
** Co says its experimental cancer drug, givastomig, showed promising results when used with standard chemotherapy and immunotherapy in patients with advanced gastric cancer
** Study of 54 patients showed 77% and 73% response rates at two doses, says co
** NBP says lower dose delayed cancer progression for nearly 17 months; higher dose data pending
** Co plans global trial comparing drug to standard treatments early this year - NBP
** As of last close, stock up ~10% over the past year
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.